Op-Ed: A great genetic plundering can be legitimized at COP16
Without strong safeguards, the multilateral mechanism for digital sequence information co
Litigating the right to health in court: Best practices regarding high-cost technologies
By María Natalia Echegoyemberry
Public Pharma vs. abusive prices: the case of the latest HIV-prevention drug
The high price tag on the HIV drug lenacapavir underscores the widespread dysfunction within Big Pharma
29 years without Jonas Salk: against the normalization of the absurd
Nearly three decades after Jonas Salk’s passing, hi